Finance

Beta
Lists
CRL:NYSE
Charles River Lbrtrs ntrntl Inc
$212.71
+5.25%
(+10.61) 1D
$210.00
-1.27% (-2.71)
After hours
Closed: Jun 25, 4:00:03 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRL...
Open
$203.90
High
$213.90
Low
$202.78
Mkt. cap
10.25B
Avg. vol.
869.04K
Volume
1.54M
52-wk high
$228.88
52-wk low
$144.26
EPS
-$3.76
Beta
1.46
Shares outstanding
48.17M
No. of employees
19K
Open
$203.90
High
$213.90
Low
$202.78
Mkt. cap
10.25B
Avg. vol.
869.04K
Volume
1.54M
52-wk high
$228.88
52-wk low
$144.26
EPS
-$3.76
Beta
1.46
Shares outstanding
48.17M
No. of employees
19K
News stories
From sources across the web
Profile
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients. Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs. As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL. Wikipedia
About Charles River Lbrtrs ntrntl Inc
CEOJames C. Foster
Employees19K
Founded1947
HeadquartersWilmington, Massachusetts, United States
SectorHealth care
Websitecriver.com
Analyst ratings
Based on 12 analysts giving stock ratings to CRL in the past 3 months
Strong buy
Buy
10
Hold
2
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for CRL in the last 3 months.
Highest
Current $212.71
$235.00 (+10.48%)
Average
$208.40 (-2.03%)
Lowest
$160.00 (-24.78%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kallum Titchmarsh
Morgan Stanley
Buy
Upgraded
$185.00
-13%
06/18/2026
Luke Sergott
Barclays
Buy
Maintained
$220.00
+3.4%
06/08/2026
Michael Ryskin
Bank of America Securities
Buy
Maintained
-
-
06/05/2026
Ryan Halsted
RBC Capital
Buy
Reiterated
$215.00
+1.1%
06/04/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$235.00
+10.5%
06/04/2026
Max Smock
William Blair
Buy
Maintained
-
-
06/02/2026
Michael Luo CFA
CLSA
Buy
Upgraded
$219.00
+3%
05/29/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$220.00
+3.4%
05/08/2026
David Windley
Jefferies
Buy
Maintained
$225.00
+5.8%
05/08/2026
Eric Coldwell
Robert W. Baird
Buy
Maintained
$213.00
+0.1%
05/08/2026
Ann Hynes
Mizuho Securities
Hold
Maintained
$192.00
-9.7%
05/08/2026
Charles Weston
RBC Capital
Buy
Initiated
$215.00
+1.1%
04/13/2026
Casey Woodring
J.P. Morgan
Hold
Reiterated
$160.00
-24.8%
04/13/2026
Dan Leonard
UBS
Hold
Maintained
$175.00
-17.7%
02/25/2026
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.06 / $1.95
+5.42%beat
Revenue / Est. (USD)
995.83M / 979.47M
+1.67%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.03B
1.00B
994.23M
995.83M
Cost of goods sold
648.60M
652.72M
665.36M
672.79M
Cost of revenue
648.60M
652.72M
665.36M
672.79M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
185.82M
173.64M
192.02M
149.12M
Operating expense
211.51M
201.05M
284.04M
164.46M
Total operating expenses
860.10M
853.77M
949.40M
837.25M
Operating income
172.03M
151.08M
44.83M
158.58M
Other non operating income
154.00K
-22.62M
27.72M
-123.11M
EBT including unusual items
71.42M
87.20M
-294.10M
-29.94M
EBT excluding unusual items
143.32M
104.48M
35.18M
8.62M
Income tax expense
18.72M
31.64M
-17.81M
-15.14M
Effective tax rate
26.22%
36.29%
6.06%
50.56%
Other operating expenses
-
-
-
-
Net income
52.33M
54.42M
-276.56M
-14.84M
Net profit margin
5.07%
5.42%
-27.82%
-1.49%
Earnings per share
3.12
2.43
2.39
2.06
Interest and investment income
1.10M
1.42M
1.02M
1.03M
Interest expense
-29.97M
-25.40M
-23.78M
-26.74M
Net interest expenses
-28.87M
-23.98M
-22.76M
-25.71M
Depreciation and amortization charges
-
-
-
-
EBITDA
327.04M
165.25M
169.61M
225.73M
Gain or loss from assets sale
-
-
-
117.98M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of CRL
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer